.@BioCentury's Wednesday news roundup features Chinese approval of BeiGene's BTK inhibitor for two cancers, plus news from Novartis, Merck-Vaxxas, Antibe, Mirum and more $BGNE $MRK $NVS $NVAX $ATE $MIRM $AVEO https://t.co/Y4AmmQ8LdL